urethra cancer
Disease Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:734
Name urethra cancer
Definition An urinary tract cancer that derives_from the tissues of the urethra.
Source DiseaseOntology.org
Alt Ids DOID:737
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urethra cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Completed USA 1
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01688999 Phase II Cabozantinib Cabozantinib for Advanced Urothelial Cancer Completed USA 0
NCT03023319 Phase I Bosutinib + Pemetrexed Disodium Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Completed USA 0
NCT03171025 Phase II Nivolumab Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT) Active, not recruiting USA 0
NCT03430895 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Completed USA 0
NCT03582475 Phase I Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Active, not recruiting USA 0
NCT05756569 Phase II Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Recruiting USA 0
NCT05987241 Phase II Nivolumab Nivolumab + Relatlimab Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Recruiting USA | CAN 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Active, not recruiting BRA 0
NCT07163325 Phase I EP102 EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors Recruiting NLD | ESP | CZE | BEL 0